HEPARIN SODIUM & DEXTROSE 5% IN VIAFLEX LIQ 5 G / 100 ML
DEXTROSE : 5 G / 100 ML HEPARIN SODIUM : 5000 UNIT / 100 ML · DIN 01900757 · BAXTER CORPORATION
Health Canada status: CANCELLED POST MARKET
What is HEPARIN SODIUM & DEXTROSE 5% IN VIAFLEX LIQ?
HEPARIN SODIUM & DEXTROSE 5% IN VIAFLEX LIQ 5 G / 100 ML contains DEXTROSE : 5 G / 100 ML HEPARIN SODIUM : 5000 UNIT / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 01900757, held by BAXTER CORPORATION, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 01-Feb-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is HEPARIN SODIUM & DEXTROSE 5% IN VIAFLEX LIQ called?
Also recorded in Canada as: glucose 0.4 MG/MG Oral Gel [Glutose] (US), glucose 50 MG/ML Oral Solution [Enfamil Glucose] (US), glucose 4000 MG Chewable Tablet [Dex4] (US), glucose 0.4 MG/MG Oral Gel [Glucoburst] (US), cholecalciferol 6.67 UNT/ML / glucose 250 MG/ML Oral Solution [ReliOn Glucose] (US), glucose 1000 MG Chewable Tablet [Dex4] (US), glucose 0.774 MG/MG Oral Gel [Insta-Glucose] (US), glucose 0.45 MG/MG Oral Gel [Dex4] (US), glucose 254 MG/ML Oral Solution [Dex4] (US), glucose 0.4 MG/MG Oral Gel [Dex4] (US), fructose 374 MG/ML / glucose 374 MG/ML / phosphoric acid 4.3 MG/ML Oral Solution [Emetrol] (US), fructose 175 MG / glucose 968 MG / sodium citrate 230 MG Chewable Tablet (US), glucose 166.7 MG/ML Oral Solution (US), glucose 150 MG/ML Injectable Solution (US), cholecalciferol 6.67 UNT/ML / glucose 250 MG/ML Oral Solution (US).
Product details and regulatory record
| DIN | 01900757 |
|---|---|
| Brand name | HEPARIN SODIUM & DEXTROSE 5% IN VIAFLEX LIQ |
| Generic / active ingredient | DEXTROSE : 5 G / 100 ML HEPARIN SODIUM : 5000 UNIT / 100 ML |
| Manufacturer | BAXTER CORPORATION |
| Strength | 5 G / 100 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B01AB51 HEPARIN, COMBINATIONS |
| AHFS class | 20:12.04.16 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 01-Feb-2011 |
| Original market date | 1991-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 01900757 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1900757 |
| Brand name | HEPARIN SODIUM & DEXTROSE 5% IN VIAFLEX LIQ |
| Active ingredient / INN | DEXTROSE : 5 G / 100 ML HEPARIN SODIUM : 5000 UNIT / 100 ML |
| ATC code | B01AB51 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B01 |
| AHFS class | 20:12.04.16 |
| Health Canada schedule | Ethical |
| Biosimilar biologic | No |
| Market authorization holder | BAXTER CORPORATION |
Which pack is which?
| Strength on the label | 5 G / 100 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
What can be used instead?
Other Canadian products sharing ATC code B01AB51 HEPARIN, COMBINATIONS. 4 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| HEPARIN SOD AND 0.9% SOD CHLORIDE INJ | 2 UNIT | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00828750 |
| HEPARIN SODIUM 20000UNITS IN 5% DEXTROSE INJ | 4000 UNIT / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 02209713 |
| HEPARIN SODIUM 25000UNITS IN 5% DEXTROSE INJ | 5 G / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 02209721 |
| HEPARIN SODIUM IN 5% DEXTROSE INJECTION, 25000UNIT/500ML | 5 G / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01935941 |
| HEPARIN SODIUM & 5% DEXTROSE INJECTION LIQ | 5 G / 100 ML | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | DIN 02008181 |
| HEPARIN SODIUM AND DEXTROSE 5% INJ USP | 5 G / 100 ML | LIQUID | BAXTER CORPORATION | CANCELLED POST MARKET | DIN 01913255 |
| HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION | 430 MG / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | DORMANT | DIN 01935933 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.